Silexion Therapeutics Corp financial data

Symbol
SLXN, SLXNW on Nasdaq
Location
12 Abba Hillel Road, Ramat Gan, Israel
State of incorporation
Cayman Islands
Fiscal year end
December 31
Former names
Biomotion Sciences (to 8/15/2024)
Latest financial report
10-Q - Q3 2024 - Nov 14, 2024

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 9.77M shares
Common Stock, Shares, Outstanding 11.2M shares
Common Stock, Value, Issued 1K USD
Weighted Average Number of Shares Outstanding, Basic 5.83M shares +480%
Weighted Average Number of Shares Outstanding, Diluted 5.83M shares +480%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 3.22M USD +501%
General and Administrative Expense 4.82M USD +2359%
Operating Income (Loss) -8.04M USD -999%
Nonoperating Income (Expense) 3.82M USD +5208%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -11.9M USD -1377%
Income Tax Expense (Benefit) 2K USD -66.7%
Net Income (Loss) Attributable to Parent -11.9M USD -1366%
Earnings Per Share, Basic 2.03 USD/shares +160%
Earnings Per Share, Diluted 2.03 USD/shares +160%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 1.97M USD
Other Assets, Current 80K USD
Assets, Current 3.05M USD
Property, Plant and Equipment, Net 35K USD
Operating Lease, Right-of-Use Asset 0 USD
Assets 3.09M USD
Accounts Payable, Current 799K USD
Employee-related Liabilities, Current 687K USD
Liabilities, Current 3.58M USD
Operating Lease, Liability, Noncurrent 0 USD
Liabilities 7.67M USD
Convertible Preferred Stock, Nonredeemable or Redeemable, Issuer Option, Value 0 USD
Retained Earnings (Accumulated Deficit) -41.6M USD
Stockholders' Equity Attributable to Parent -4.58M USD
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest -4.58M USD +1.46%
Liabilities and Equity 3.09M USD

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -2.65M USD -287%
Net Cash Provided by (Used in) Financing Activities 2.92M USD
Net Cash Provided by (Used in) Investing Activities -16K USD -122%
Common Stock, Shares Authorized 200M shares
Common Stock, Shares, Issued 11.2M shares
Common Stock, Par or Stated Value Per Share 0 USD/shares
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 2.02M USD -65.2%
Interest Paid, Excluding Capitalized Interest, Operating Activities 0 USD -100%
Depreciation 22K USD +120%
Payments to Acquire Property, Plant, and Equipment 16K USD +167%
Operating Lease, Liability, Current 0 USD
Additional Paid in Capital 37M USD
Share-based Payment Arrangement, Expense 5.8M USD +18019%